Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives $59.60 Average Price Target from Analysts

Oruka Therapeutics, Inc. (NASDAQ:ORKA) has received a consensus recommendation of “Moderate Buy” from the eleven brokerages that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and ten have given a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $59.60.

A number of equities analysts have commented on ORKA shares. Guggenheim reaffirmed a “buy” rating and set a $60.00 price objective on shares of Oruka Therapeutics in a research report on Friday, March 13th. BTIG Research reissued a “buy” rating and issued a $73.00 price objective on shares of Oruka Therapeutics in a research report on Friday, March 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Thursday, January 22nd. Barclays upped their price target on shares of Oruka Therapeutics from $48.00 to $50.00 and gave the company an “overweight” rating in a research note on Friday, March 13th. Finally, Wall Street Zen raised shares of Oruka Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, March 16th.

Insider Activity at Oruka Therapeutics

In related news, CEO Lawrence Otto Klein sold 1,729 shares of Oruka Therapeutics stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $41.30, for a total transaction of $71,407.70. Following the completion of the sale, the chief executive officer directly owned 927,309 shares of the company’s stock, valued at approximately $38,297,861.70. This trade represents a 0.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Joana Goncalves sold 7,641 shares of the business’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $40.91, for a total value of $312,593.31. Following the completion of the sale, the insider owned 33,377 shares of the company’s stock, valued at $1,365,453.07. This trade represents a 18.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 23,765 shares of company stock worth $849,575 in the last ninety days. 24.69% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ORKA. Fairmount Funds Management LLC increased its position in Oruka Therapeutics by 9.9% during the third quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company’s stock worth $71,252,000 after acquiring an additional 333,340 shares during the period. Avoro Capital Advisors LLC bought a new stake in Oruka Therapeutics in the 3rd quarter valued at about $25,640,000. Financial Enhancement Group LLC acquired a new position in shares of Oruka Therapeutics during the 3rd quarter worth approximately $631,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new position in shares of Oruka Therapeutics during the third quarter worth approximately $296,000. Finally, B Group Inc. increased its holdings in shares of Oruka Therapeutics by 28.8% during the second quarter. B Group Inc. now owns 75,000 shares of the company’s stock worth $841,000 after purchasing an additional 16,785 shares during the period. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Stock Down 2.2%

ORKA opened at $44.48 on Friday. Oruka Therapeutics has a 12-month low of $5.49 and a 12-month high of $47.25. The stock has a market cap of $2.20 billion, a price-to-earnings ratio of -23.91 and a beta of -0.38. The business has a 50 day moving average of $35.34 and a 200-day moving average of $29.42.

Oruka Therapeutics (NASDAQ:ORKA) last posted its earnings results on Thursday, March 12th. The company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.16. As a group, analysts expect that Oruka Therapeutics will post -3.41 earnings per share for the current year.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.